Search

Your search keyword '"Hoster, Eva"' showing total 6 results
Start Over Author "Hoster, Eva" Journal hemasphere
6 results on '"Hoster, Eva"'

1. Inferior Outcomes of EU Versus US Patients Treated With CD19 CAR-T for Relapsed/Refractory Large B-cell Lymphoma: Association With Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization, and CAR-T Product Use

Author

Bücklein, Veit, primary, Perez, Ariel, additional, Rejeski, Kai, additional, Iacoboni, Gloria, additional, Jurinovic, Vindi, additional, Holtick, Udo, additional, Penack, Olaf, additional, Kharboutli, Soraya, additional, Blumenberg, Viktoria, additional, Ackermann, Josephine, additional, Frölich, Lisa, additional, Johnson, Grace, additional, Patel, Kedar, additional, Arciola, Brian, additional, Mhaskar, Rahul, additional, Wood, Anthony, additional, Schmidt, Christian, additional, Albanyan, Omar, additional, Gödel, Philipp, additional, Hoster, Eva, additional, Bullinger, Lars, additional, Mackensen, Andreas, additional, Locke, Frederick, additional, von Bergwelt, Michael, additional, Barba, Pere, additional, Subklewe, Marion, additional, and Jain, Michael D., additional

Published
2023
Full Text
View/download PDF

2. Genetic and Microenvironment Features Do Not Distinguish Follicular Lymphoma Patients Requiring Immediate or Deferred Treatment

Author

Stevens, Wendy B. C., primary, Los-de Vries, G. Tjitske, additional, Langois-Jacques, Carole, additional, Clear, Andrew J., additional, Stathi, Phylicia, additional, Sander, Birgitta, additional, Rosenwald, Andreas, additional, Calaminici, Maria, additional, Hoster, Eva, additional, Hiddemann, Wolfgang, additional, Gaulard, Philippe, additional, Salles, Gilles, additional, Klapper, Wolfram, additional, Xerri, Luc, additional, Burton, Catherine, additional, Tooze, Reuben M., additional, Smith, Alexandra G., additional, Buske, Christian, additional, Scott, David W., additional, Natkunam, Yasodha, additional, Advani, Ranjana, additional, Sehn, Laurie H., additional, Raemaekers, John, additional, Gribben, John, additional, Lockmer, Sandra, additional, Kimby, Eva, additional, Kersten, Marie José, additional, Maucort-Boulch, Delphine, additional, Ylstra, Bauke, additional, van Dijk, Erik, additional, and de Jong, Daphne, additional

Published
2023
Full Text
View/download PDF

3. Immunochemotherapy and Maintenance With Obinutuzumab or Rituximab in Patients With Previously Untreated Marginal Zone Lymphoma in the Randomized GALLIUM Trial

Author

Herold, Michael, primary, Hoster, Eva, additional, Janssens, Ann, additional, McCarthy, Helen, additional, Tedeschi, Alessandra, additional, Pocock, Chris, additional, Rosta, Andras, additional, Trněný, Marek, additional, Nielsen, Tina G., additional, Knapp, Andrea, additional, Hiddemann, Wolfgang, additional, and Marcus, Robert, additional

Published
2022
Full Text
View/download PDF

4. Rituximab Maintenance Versus Observation After Immunochemotherapy (R-CHOP, R-MCP, and R-FCM) in Untreated Follicular Lymphoma Patients: A Randomized Trial of the Ostdeutsche Studiengruppe Hämatologie und Onkologie and the German Low-Grade Lymphoma Study Group

Author

Hirt, Carsten, primary, Hoster, Eva, additional, Unterhalt, Michael, additional, Hänel, Mathias, additional, Prange-Krex, Gabriele, additional, Forstpointner, Roswitha, additional, Florschütz, Axel, additional, Graeven, Ullrich, additional, Frickhofen, Norbert, additional, Wulf, Gerald, additional, Lengfelder, Eva, additional, Lerchenmüller, Christian, additional, Schlag, Rudolf, additional, Dierlamm, Judith, additional, Fischer von Weikersthal, Ludwig, additional, Ahmed, Asima, additional, Harich, Hanns-Detlev, additional, Rosenwald, Andreas, additional, Klapper, Wolfram, additional, Dreyling, Martin, additional, Hiddemann, Wolfgang, additional, and Herold, Michael, additional

Published
2021
Full Text
View/download PDF

5. Rituximab With Involved Field Irradiation for Early-stage Nodal Follicular Lymphoma

Author

Herfarth, Klaus, Borchmann, Peter, Schnaidt, Sven, Hohloch, Karin, Budach, Volker, Engelhard, Marianne, Viardot, Andreas, Engenhart-Cabillic, Rita, Keller, Ulrich, Reinartz, Gabriele, Eich, Hans-Theodor, Witzens-Harig, Mathias, Hess, Clemens F., Dörken, Bernd, Dürig, Jan, Wiegel, Thomas, Hiddemann, Wolfgang, Hoster, Eva, Pott, Christiane, and Dreyling, Martin

Subjects
lcsh:RC633-647.5, ComputingMethodologies_DOCUMENTANDTEXTPROCESSING, lcsh:Diseases of the blood and blood-forming organs, Article
Abstract

Supplemental Digital Content is available in the text, The MabThera and Involved field Radiotherapy study investigated efficacy and safety of involved field (IF) radiotherapy in combination with the anti-CD20 antibody Rituximab for early-stage follicular lymphoma (FL) in a prospective, single-arm multicenter phase 2 design. Eighty-five stage I–II FL patients received 8 cycles of Rituximab (375 mg/m2) and IF irradiation (30/40 Gy). The primary endpoint was progression-free survival (PFS) 2 years from treatment start. Secondary endpoints were overall survival (OS), complete response rates, toxicity, quality of life, and minimal residual disease (MRD) response with protocol defined visits up to month 30. For the primary endpoint, PFS at 2 years was 85% for the intention-to-treat set. Long-term data were captured in selected sites and evaluated as post hoc analysis in the per protocol (PP) set: PFS and OS were 78% and 96% at 5 years with a median follow-up of 66 or 78 months, respectively. There were 17/76 recurrences in the PP set, of which 14 were outside the radiation volume only. MRD analyses revealed a clonal marker in 36% of patients at diagnosis. All but 1 marker positive patients experienced a molecular treatment response. There were 13 serious adverse events (4 related to the therapy) during the first 30 months. IF radiotherapy combined with Rituximab is well tolerated and highly efficient with low rates of recurrence in the first years in early-stage FL. The efficacy is comparable with more aggressive therapy approaches without compromising the quality of life and maintains for an extended follow-up of more than 5 years.

Published
2018

6. Molecular Cytogenetic Profiling Reveals Similarities and Differences Between Localized Nodal and Systemic Follicular Lymphomas.

Author

Horn H, Jurinovic V, Leich E, Kalmbach S, Bausinger J, Staiger AM, Kurz KS, Möller P, Bernd HW, Feller AC, Koch K, Klapper W, Stein H, Hansmann ML, Hartmann S, Scheubeck G, Dreyling M, Hiddemann W, Herfarth K, Engelhard M, Rosenwald A, Hoster E, and Ott G

Abstract

Recently, we have developed novel highly promising gene expression (GE) classifiers discriminating localized nodal (LFL) from systemic follicular lymphoma (SFL) with prognostic impact. However, few data are available in LFL especially concerning hotspot genetic alterations that are associated with the pathogenesis and prognosis of SFL. A total of 144 LFL and 527 SFL, enrolled in prospective clinical trials of the German Low Grade Lymphoma Study Group, were analyzed by fluorescence in situ hybridization to detect deletions in chromosomes 1p, 6q, and 17p as well as BCL2 translocations to determine their impact on clinical outcome of LFL patients. The frequency of chromosomal deletions in 1p and 17p was comparable between LFL and SFL, while 6q deletions and BCL2 translocations more frequently occurred in SFL. A higher proportion of 1p deletions was seen in BCL2 -translocation-positive LFL, compared with BCL2 -translocation-negative LFL. Deletions in chromosomes 1p, 6q, and 17p predicted clinical outcome of patients with SFL in the entire cohort, while only deletions in chromosome 1p retained its negative prognostic impact in R-CHOP-treated SFL. In contrast, no deletions in one of the investigated genetic loci predicted clinical outcome in LFL. Likewise, the presence or absence of BCL2 translocations had no prognostic impact in LFL. Despite representing a genetic portfolio closely resembling SFL, LFL showed some differences in deletion frequencies. BCL2 translocation and 6q deletion frequency differs between LFL and SFL and might contribute to distinct genetic profiles in LFL and SFL., (Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association.)

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results